{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:28:46Z","timestamp":1794097726922,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan KK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim Pharma GmbH und Co KG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017346","name":"Boehringer Ingelheim Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports\u00ae"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ekir.2025.09.049","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:21:05Z","timestamp":1760145665000},"page":"141-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Empagliflozin and Ultrafiltration Volume in Patients Undergoing Peritoneal Dialysis"],"prefix":"10.1016","volume":"11","author":[{"given":"Yohei","family":"Doi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Shinzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Arisato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyasu","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harumi","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Nakazono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Nishiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuryu","family":"Sonoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Monden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terumasa","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiki","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Isaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.09.049_bib1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s10157-015-1203-2","article-title":"Extracellular volume expansion and the preservation of residual renal function in Korean peritoneal dialysis patients: a long-term follow up study","volume":"20","author":"Rhee","year":"2016","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2025.09.049_bib2","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMra2100152","article-title":"Peritoneal dialysis","volume":"385","author":"Teitelbaum","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.09.049_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.semnephrol.2016.10.006","article-title":"Fluid overload in peritoneal dialysis patients","volume":"37","author":"Kim","year":"2017","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ekir.2025.09.049_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000520894","article-title":"Peritoneal expression of SGLT-2, GLUT1, and GLUT3 in peritoneal dialysis patients","volume":"47","author":"Schricker","year":"2022","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.ekir.2025.09.049_bib5","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.biopha.2018.10.106","article-title":"SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2","volume":"109","author":"Zhou","year":"2019","journal-title":"Biomed Pharmacother Biomed Pharmacother"},{"key":"10.1016\/j.ekir.2025.09.049_bib6","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3390\/biom10111573","article-title":"SGLT2 inhibition by intraperitoneal dapagliflozin mitigates peritoneal fibrosis and ultrafiltration failure in a mouse model of chronic peritoneal exposure to high-glucose dialysate","volume":"10","author":"Balzer","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.ekir.2025.09.049_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107374","article-title":"Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-\u03b2\/Smad signaling","volume":"93","author":"Shentu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ekir.2025.09.049_bib8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12882-024-03683-y","article-title":"SGLT-2 inhibitors in chronic peritoneal dialysis patients: a follow-up study","volume":"25","author":"Lai","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.09.049_bib9","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3390\/medicina60081198","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors in diabetic and non-diabetic patients with advanced chronic kidney disease in peritoneal dialysis on residual kidney function: in real-world data","volume":"60","author":"Moral Berrio","year":"2024","journal-title":"Medicina (Kaunas Lithuania)"},{"key":"10.1016\/j.ekir.2025.09.049_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12882-023-03429-2","article-title":"Dapagliflozin in peritoneal dialysis patients: a pilot study evaluating peritoneal membrane function","volume":"25","author":"Hamdan","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.09.049_bib11","article-title":"The use of SGLT2 inhibitors in peritoneal dialysis patients: a shade of light on dapagliflozin","volume":"01","author":"Al-Hwiesh","year":"2022","journal-title":"Arch Nephrol Urol"},{"key":"10.1016\/j.ekir.2025.09.049_bib12","series-title":"Japan Registry of Clinical Trials (jRCT)","year":"2025"},{"key":"10.1016\/j.ekir.2025.09.049_bib13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10157-024-02467-w","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on ultrafiltration in patients with peritoneal dialysis: a protocol for a randomized, double-blind, placebo-controlled, crossover trial (EMPOWERED)","volume":"28","author":"Doi","year":"2024","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2025.09.049_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1525-139X.1990.tb00029.x","article-title":"The fast peritoneal equilibration test","volume":"3","author":"Twardowski","year":"1990","journal-title":"Semin Dial"},{"key":"10.1016\/j.ekir.2025.09.049_bib15","first-page":"2322","article-title":"Daily peritoneal ultrafiltration predicts patient and technique survival in anuric peritoneal dialysis patients","volume":"25","author":"Lin","year":"2010","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc"},{"key":"10.1016\/j.ekir.2025.09.049_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/08968608221080170","article-title":"Dual SGLT1\/SGLT2 inhibitor phlorizin reduces glucose transport in experimental peritoneal dialysis","volume":"43","author":"Martus","year":"2023","journal-title":"Perit Dial Int J Int Soc Perit Dial"},{"key":"10.1016\/j.ekir.2025.09.049_bib17","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1681\/ASN.2022040474","article-title":"Phloretin improves ultrafiltration and reduces glucose absorption during peritoneal dialysis in rats","volume":"33","author":"Bergling","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.09.049_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/08968608231165865","article-title":"Blockade of sodium-glucose co-transporters improves peritoneal ultrafiltration in uraemic rodent models","volume":"44","author":"Vorobiov","year":"2024","journal-title":"Perit Dial Int J Int Soc Perit Dial"},{"key":"10.1016\/j.ekir.2025.09.049_bib19","article-title":"Canagliflozin alleviates high glucose-induced peritoneal fibrosis via HIF-1\u03b1 inhibition","volume":"14","author":"Wang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ekir.2025.09.049_bib20","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1681\/ASN.V12102158","article-title":"Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study","volume":"12","author":"Bargman","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.09.049_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.09.049_bib22","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.09.049_bib23","article-title":"The urinary glucose excretion by sodium-glucose cotransporter 2 inhibitor in patients with different levels of renal function: a systematic review and meta-analysis","volume":"12","author":"Hu","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ekir.2025.09.049_bib24","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2024.02.020","article-title":"Water conservation overrides osmotic diuresis during SGLT2 inhibition in patients with heart failure","volume":"83","author":"Marton","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2025.09.049_bib25","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2025.09.049_bib26","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1111\/dom.14779","article-title":"Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: a post hoc mediation analysis of the CANVAS trial","volume":"24","author":"Sen","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2025.09.049_bib27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1681\/ASN.0000000000000271","article-title":"Effects of empagliflozin on fluid overload, weight, and blood pressure in CKD","volume":"35","author":"Mayne","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.09.049_bib28","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2025.09.049_bib29","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3389\/fphys.2018.01575","article-title":"Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients","volume":"9","author":"Uthman","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.ekir.2025.09.049_bib30","article-title":"Empagliflozin reduces oxidative stress through inhibition of the novel inflammation\/NHE\/[Na(+)](c)\/ROS-pathway in human endothelial cells","volume":"146","author":"Uthman","year":"2022","journal-title":"Biomed Pharmacother Biomed Pharmacother"},{"key":"10.1016\/j.ekir.2025.09.049_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.664181","article-title":"Sodium-glucose CoTransporter-2 inhibitor empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of AMPK-mTOR signaling pathway-mediated autophagy","volume":"12","author":"Ren","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ekir.2025.09.049_bib32","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/cvr\/cvad009","article-title":"Empagliflozin inhibits excessive autophagy through the AMPK\/GSK3\u03b2 signalling pathway in diabetic cardiomyopathy","volume":"119","author":"Madonna","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ekir.2025.09.049_bib33","doi-asserted-by":"crossref","first-page":"872","DOI":"10.34067\/KID.0006922021","article-title":"International icodextrin use and association with peritoneal membrane function, fluid removal, patient and technique survival","volume":"3","author":"Davies","year":"2022","journal-title":"Kidney360"}],"container-title":["Kidney International Reports\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925006242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925006242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T09:20:43Z","timestamp":1766481643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925006242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2468024925006242"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.09.049","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin and Ultrafiltration Volume in Patients Undergoing Peritoneal Dialysis","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports\u00ae","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.09.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}